MMP-2 dysregulation in CKD has been linked to increased levels of fibrotic markers such as collagen and α-SMA, highlighting its role as a potential therapeutic target for fibrosis in renal diseases [71,72,73]. This evidence concerns the gene MMP2 and chronic kidney disease.